遗传性铜蓝蛋白缺乏症继发铁过载的临床特征与诊疗策略

Diagnosis and Treatment of Iron Overload Secondary to Aceruloplasminemia

  • 摘要: 目的 探讨遗传性铜蓝蛋白缺乏症(aceruloplasminemia,ACP)继发铁过载的临床特征、系统化诊断流程及铁螯合治疗策略。方法 回顾性分析北京协和医院2018年12月至2025年9月确诊ACP的患者临床资料,总结其铁过载的临床表现、诊断关键点及治疗反应。结果 共4例患者确诊为ACP,均为中老年起病,均合并有糖尿病,其中3例存在进行性神经系统症状。所有患者均表现为特征性铁代谢异常:血清铁蛋白显著升高(730 ~ 12 091 ng/ mL),转铁蛋白饱和度降低(4.9% ~23.4%),铜蓝蛋白显著降低或测不出。基因检测证实均为CP基因致病性突变。ACP的诊断流程需结合临床“三联征” (糖尿病、神经症状、贫血)线索、铁代谢特征模式及影像学证据,并与遗传性血色病等铁过载疾病相鉴别。4例患者均接受铁螯合治疗(去铁酮、去铁胺或地拉罗司),其中1例经治疗后铁蛋白下降,并伴神经系统症状改善。结论 ACP的铁过载表现隐匿,其诊断依赖临床警惕性及系统的铁代谢评估;建立从临床筛查到基因检测的阶梯式诊断流程至关重要;早期、个体化的铁螯合治疗是管理铁过载、延缓多脏器损伤的核心措施。

     

    Abstract: Objective To explore the clinical features, systematic diagnostic process, and iron chelation therapy strategies of secondary iron overload in aceruloplasminemia (ACP). Methods A retrospective analysis was performed on the clinical data of patients diagnosed with aceruloplasminemia in Peking Union Medical College Hospital from December 2018 to September 2025. The clinical manifestations related to iron overload, key diagnostic points, and treatment responses were systematically summarized. Results A total of four patients were diagnosed with ACP. All of them had middle to late onset of the disease, and all had diabetes. Among them, 3 cases presented with progressive neurological symptoms. All patients showed a characteristic pattern of abnormal iron metabolism:significantly elevated serum ferritin (range:730-12 091 ng/mL), decreased transferrin saturation (range:4. 9%-23. 4%), and significantly reduced or undetectable ceruloplasmin levels. Genetic testing confirmed pathogenic mutations in the CP gene in all patients. For diagnosis, it is necessary to take the clinical "triad" (diabetes mellitus, neurological symptoms, anemia) as clues, combine with characteristic abnormalities in iron metabolism indicators and imaging evidence, and conduct differentiation from other iron overload diseases such as hereditary hemochromatosis. In terms of treatment, all the 4 patients received iron chelation therapy, including deferoxamine, deferiprone, and deferasirox. One of the patients showed a significant decrease in serum ferritin level with improvement in neurological symptoms after treatment. Conclusions Iron overload secondary to ACP has insidious manifestations, and its clinical diagnosis relies on a high degree of vigilance and systematic iron metabolism evaluation. Establishing a stepwise diagnostic process from clinical screening to genetic testing is crucial. Early initiation and implementation of individualized iron chelation therapy is a core therapeutic measure to effectively manage iron overload and delay the progression of multiple organ damage.

     

/

返回文章
返回